Rare Kidney Diseases Market Growth Outlook Through 2024-2033

Overview and Scope
Rare kidney disease is a condition where kidneys aren’t functioning correctly, waste accumulates in the body, and causes problems with your health. It is a set of renal diseases that have a low frequency in the general population, and these disorders frequently have a genetic or hereditary origin.

Sizing and Forecast
The rare kidney diseases market size has grown rapidly in recent years. It will grow from $2.52 billion in 2023 to $2.8 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to increased disease recognition, orphan drug designations, patient advocacy and awareness, global collaborations in research..

The rare kidney diseases market size is expected to see strong growth in the next few years. It will grow to $4.07 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to emergence of gene therapies, increasing investment in rare disease research, growing collaboration between stakeholders, global initiatives for rare diseases.. Major trends in the forecast period include patient-centric approach, real-world evidence and data analytics, regulatory developments, telemedicine and remote monitoring, global health initiatives..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Segmentation & Regional Insights
The rare kidney diseases market covered in this report is segmented –

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications
2) By Type of Molecule: Small Molecules, Biologics
3) By Route of administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration

North America was the leading region in the rare kidney disease market in 2023. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=11908&type=smp

Major Driver Impacting Market Growth
Government initiatives and funding for kidney disorders are expected to propel the growth of the rare kidney disease market going forward. A government initiative and funding are a type of government financial support given to selected entities with ideas or projects that contribute to and improve public services and the economy. The government provides aid in kidney disorders to enhance disease surveillance and improve the quality of life for persons with various kidney diseases by using a comprehensive public health strategy that includes other public health agencies and national organizations. For instance, in July 2022, The United States House Committee on Appropriations, a US-based committee of the House of Representatives, initiated various investment programs to promote kidney health. It includes $8.5 million in funding for the Centers for Disease Control and Prevention’s (CDC) chronic kidney disease program to accelerate activities to promote regular kidney disease awareness, diagnosis, and treatment. Further, a living donation investment of $1 million was made to boost the national living donor assistance center, bringing the total to $8 million in ongoing investment in innovation and research. Therefore, government initiatives and funding for kidney disorders are driving the growth of the rare kidney disease market.

Key Industry Players

Major companies operating in the rare kidney diseases market report are Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca PLC, GlaxoSmithKline PLC, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Proteostasis Therapeutics, Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., Spyryx Biosciences Inc., OxThera AB, Advicenne Pharma SA, ProQR Therapeutics NV, Reata Pharmaceuticals Inc., Savara Inc.

The rare kidney diseases market report table of contents includes:

1. Executive Summary
2. Rare Kidney Diseases Market Characteristics
3. Rare Kidney Diseases Market Trends And Strategies
4. Rare Kidney Diseases Market – Macro Economic Scenario
5. Global Rare Kidney Diseases Market Size and Growth
.
.
.
31. Rare Kidney Diseases Market Other Major And Innovative Companies
32. Global Rare Kidney Diseases Market Competitive Benchmarking
33. Global Rare Kidney Diseases Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Rare Kidney Diseases Market
35. Rare Kidney Diseases Market Future Outlook and Potential Analysis
36.Appendix

Explore the trending research reports from TBRC:

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model